trending Market Intelligence /marketintelligence/en/news-insights/trending/BsKL0Y40FJfOXKc672yx1Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

S&P revises outlook on PRA Health after Symphony Health deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

S&P revises outlook on PRA Health after Symphony Health deal

S&P Global Ratings affirmed the BB long-term corporate credit rating on PRA Health Sciences Inc. and revised the outlook to stable from positive after its decision to acquire Symphony Health Solutions for $530 million in cash.

The outlook revision reflects S&P's view that the deal is credit negative due to the increase in adjusted debt leverage. For the long term, adjusted debt leverage is expected to stay in the 3x to 4x range and S&P believes it is less likely to reach below 3x.

In addition, the rating agency said PRA Health's EBITDA growth, cash generation and mandatory debt repayment facilitate rapid deleveraging.

S&P said despite PRA Health's vulnerability to trial cancellations and delays such as other contract research organizations, the company's growth is faster than the industry average, indicating market share gains primarily driven by the addition of a few large clients.

S&P Global Ratings and S&P Global Market Intelligence are owned by S&P Global Inc.